Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
Instil Bio (Nasdaq: TIL), a clinical-stage biopharmaceutical firm, will participate in the Cell Therapy Panel at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:10 a.m. ET. The panel discussion will focus on their tumor infiltrating lymphocyte (TIL) therapies aimed at treating patients with cancer. Interested parties can access a live webcast at this link, with an archived replay available for 90 days post-event. For more details, visit www.instilbio.com.
- None.
- None.
DALLAS, March 02, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will be participating in a Cell Therapy Panel at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 9:10 a.m. ET.
A live webcast of the presentation may be accessed at: https://wsw.com/webcast/cowen108/panel20/2319930 or by visiting the News & Events section of the Instil Bio website at www.instilbio.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.
About Instil Bio
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.
Contacts:
| Media Contact: 1-833-446-7845 Ext. 1009 mediarelations@instilbio.com Brendan Payne Stern Investor Relations 1-212-362-1200 brendan.payne@sternir.com |
FAQ
What is Instil Bio's stock symbol?
When is Instil Bio participating in the Cowen Annual Health Care Conference?
How can I watch the Instil Bio presentation at the conference?
What therapies is Instil Bio focused on developing?
What is Instil Bio's lead product candidate?
